HSD17B12

Entrez Summary: N/A
UniProt Summary: Catalyzes the second of the four reactions of the long- chain fatty acids elongation cycle. This endoplasmic reticulum- bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme has a 3-ketoacyl-CoA reductase activity, reducing 3- ketoacyl-CoA to 3-hydroxyacyl-CoA, within each cycle of fatty acid elongation. Thereby, it may participate in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. May also catalyze the transformation of estrone (E1) into estradiol (E2) and play a role in estrogen formation. {ECO:0000269|PubMed:12482854, ECO:0000269|PubMed:16166196}.

Pfam Domains GO Terms

Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)

Screen	Score
FTY720 3μM R08 exp483	-3.34
Lead acetate 2000μM R08 exp497	-2.78
NN-Dimethylsphingosine 2.5μM R08 exp508	-2.65
Calcium Ionophore 0.4μM R07 exp342	-2.55
Tubacin 1.6μM R07 exp416	-2.24
Lead acetate 2000μM R08 exp498 no dilution day6	-2.21
Momordin-Ic 10μM R08 exp506	-2.19
Ethanol 0.003 R08 exp437	-2.08
Hydroxychloroquine 30μM R08 exp490	-1.99
Ethambutol 25μM R08 exp481	-1.79
Thioridazine 5μM R08 exp530	-1.72
Clomiphene 4.4μM R02 exp68	1.73
QNZ 0.01μM R05 exp241	1.82
BI-2536 0.0042μM R03 exp95	1.84
GSK-J4 1-1.25μM to day4 R07 exp363	1.93
QNZ 0.01μM R08 exp439	2.05
Mubritinib 0.2μM R01 exp48	2.13
Mubritinib 0.2μM R02 exp65	2.2
Nifuroxazide 5μM R03 exp102	2.2
TRAIL 5ng/ml R00 exp35	2.5
Fluvastatin 2.2μM R06 exp282	2.52
Phenformin 20μM R03 exp143	2.59
Citral 75μM R06 exp275	2.69
Cerivastatin 0.15μM R05 exp226	2.76
Rotenone 0.07μM R08 exp431	3.05

Global Fraction of Cell Lines Where Essential: 110/739

Tissue	Fraction Of Cell Lines Where Essential
1290807.0	0/1
909776.0	1/1
bile duct	1/28
blood	5/28
bone	0/26
breast	4/33
central nervous system	14/56
cervix	0/4
colorectal	1/17
esophagus	3/13
fibroblast	1/1
gastric	1/16
kidney	5/21
liver	7/20
lung	11/75
lymphocyte	2/16
ovary	2/26
pancreas	2/24
peripheral nervous system	3/16
plasma cell	0/15
prostate	1/1
skin	3/24
soft tissue	3/9
thyroid	1/2
upper aerodigestive	4/22
urinary tract	6/29
uterus	0/5

Expression Distribution

3-oxo-arachidoyl-CoA reductase activity
3-oxo-cerotoyl-CoA reductase activity
3-oxo-lignoceroyl-CoA reductase activity
3-oxo-behenoyl-CoA reductase activity
estradiol 17-beta-dehydrogenase activity
estrogen biosynthetic process
long-chain fatty-acyl-CoA biosynthetic process
long-chain fatty-acyl-CoA metabolic process
fibronectin binding
estrogen metabolic process
fatty-acyl-CoA biosynthetic process
fatty-acyl-CoA metabolic process
thioester biosynthetic process
acyl-CoA biosynthetic process
steroid hormone biosynthetic process
ribonucleoside bisphosphate biosynthetic process
purine nucleoside bisphosphate biosynthetic process
nucleoside bisphosphate biosynthetic process
hormone biosynthetic process
collagen binding
fatty acid derivative biosynthetic process
thioester metabolic process
acyl-CoA metabolic process
fatty acid biosynthetic process
cellular hormone metabolic process
positive regulation of cell-substrate adhesion
steroid biosynthetic process
nucleoside bisphosphate metabolic process
purine nucleoside bisphosphate metabolic process
ribonucleoside bisphosphate metabolic process
coenzyme biosynthetic process
purine ribonucleotide biosynthetic process
purine nucleotide biosynthetic process
ribonucleotide biosynthetic process
fatty acid derivative metabolic process
ribose phosphate biosynthetic process
heparin binding
purine-containing compound biosynthetic process
sulfur compound biosynthetic process
monocarboxylic acid biosynthetic process